耐受性-话题@MedSci

#耐受性#

144篇内容 | 3925人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2162168, encodeId=c2c3216216891, content=<a href='/topic/show?id=4bbf8228ef5' target=_blank style='color:#2F92EE;'>#肺结节#</a> <a href='/topic/show?id=82e38208872' target=_blank style='color:#2F92EE;'>#肺叶#</a><a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=病例分享：75岁高龄又主动脉瘤放过支架，查出肺结节并随访进展，我叫他手术，对吗？, objectType=article, longId=795438, objectId=417de95438f4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221107/1667834912742_8252897.webp, objectUrl=/article/show_article.do?id=417de95438f4, replyNumber=0, likeNumber=94, createdTime=2023-10-11, rootId=0, userName=litao2022, userId=1ff65466529, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=417de95438f4, moduleTitle=病例分享：75岁高龄又主动脉瘤放过支架，查出肺结节并随访进展，我叫他手术，对吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=417de95438f4)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1417756, encodeId=24e7141e756dd, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=JCC: 硫嘌呤治疗克罗恩病失败后硫鸟嘌呤与甲氨蝶呤可以作为二线治疗药物并有良好耐受性, objectType=article, longId=739130, objectId=46cce3913089, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46cce3913089, replyNumber=0, likeNumber=114, createdTime=2022-09-14, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46cce3913089, moduleTitle=JCC: 硫嘌呤治疗克罗恩病失败后硫鸟嘌呤与甲氨蝶呤可以作为二线治疗药物并有良好耐受性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46cce3913089)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417755, encodeId=2a9b141e75575, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Lancet：联合用药治疗糖尿病周围神经病变性疼痛的效果与单一用药相似，联合用药耐受性好, objectType=article, longId=736898, objectId=4bf8e36898c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4bf8e36898c1, replyNumber=0, likeNumber=103, createdTime=2022-08-26, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4bf8e36898c1, moduleTitle=Lancet：联合用药治疗糖尿病周围神经病变性疼痛的效果与单一用药相似，联合用药耐受性好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4bf8e36898c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417754, encodeId=d353141e754f8, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=吡非尼酮胶囊在中国肺纤维化人群中的耐受性研究, objectType=article, longId=732522, objectId=f8cae3252216, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8cae3252216, replyNumber=0, likeNumber=105, createdTime=2022-07-17, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8cae3252216, moduleTitle=吡非尼酮胶囊在中国肺纤维化人群中的耐受性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8cae3252216)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417753, encodeId=7dcb141e753f0, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=JAMA Dermatol：Nomacopan治疗大疱性类天疱疮老年患者的耐受性良好，疗效佳, objectType=article, longId=732192, objectId=fe13e321925b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe13e321925b, replyNumber=0, likeNumber=90, createdTime=2022-07-13, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe13e321925b, moduleTitle=JAMA Dermatol：Nomacopan治疗大疱性类天疱疮老年患者的耐受性良好，疗效佳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe13e321925b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417752, encodeId=ee2e141e75230, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Br J Radiol：老年非黑素瘤皮肤癌患者的短疗程加速放疗耐受性良好，高剂量的效果更佳, objectType=article, longId=732189, objectId=8459e3218955, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8459e3218955, replyNumber=0, likeNumber=102, createdTime=2022-07-13, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8459e3218955, moduleTitle=Br J Radiol：老年非黑素瘤皮肤癌患者的短疗程加速放疗耐受性良好，高剂量的效果更佳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8459e3218955)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417751, encodeId=991b141e751e2, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=EBioMedicine ：CBP/β-连环蛋白抑制剂PRI-724在丙型和乙型肝炎病毒诱导的肝硬化患者中的安全性、耐受性和抗纤维化效果, objectType=article, longId=727868, objectId=a22fe2786820, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a22fe2786820, replyNumber=0, likeNumber=92, createdTime=2022-05-27, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a22fe2786820, moduleTitle=EBioMedicine ：CBP/β-连环蛋白抑制剂PRI-724在丙型和乙型肝炎病毒诱导的肝硬化患者中的安全性、耐受性和抗纤维化效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a22fe2786820)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417750, encodeId=49ab141e750df, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=JNNP:生酮饮食治疗复发性多发性硬化症的II期研究,安全性、耐受性和潜在临床益处, objectType=article, longId=727308, objectId=ab34e27308f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab34e27308f9, replyNumber=0, likeNumber=114, createdTime=2022-05-20, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab34e27308f9, moduleTitle=JNNP:生酮饮食治疗复发性多发性硬化症的II期研究,安全性、耐受性和潜在临床益处, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab34e27308f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417749, encodeId=e7eb141e749ab, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=J Eur Acad Dermatol Venereol：外用非那雄胺可明显改善毛发数量，且耐受性良好, objectType=article, longId=725899, objectId=75b2e258991e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75b2e258991e, replyNumber=0, likeNumber=138, createdTime=2022-05-02, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75b2e258991e, moduleTitle=J Eur Acad Dermatol Venereol：外用非那雄胺可明显改善毛发数量，且耐受性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75b2e258991e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417748, encodeId=1c82141e74826, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=益生元有利减肥，但随时排气很社死？加上TA，增强胃肠道耐受性！还能使益生元效果upup，改善代谢参数！, objectType=article, longId=723686, objectId=20e7e236860c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20e7e236860c, replyNumber=0, likeNumber=97, createdTime=2022-04-08, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20e7e236860c, moduleTitle=益生元有利减肥，但随时排气很社死？加上TA，增强胃肠道耐受性！还能使益生元效果upup，改善代谢参数！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20e7e236860c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417747, encodeId=8957141e747ef, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=肺动脉高压患者的运动耐受性为什么要纳入病情评估中？, objectType=article, longId=301571, objectId=44863015e119, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44863015e119, replyNumber=0, likeNumber=141, createdTime=2022-03-25, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44863015e119, moduleTitle=肺动脉高压患者的运动耐受性为什么要纳入病情评估中？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=44863015e119)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417746, encodeId=65bd141e74613, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=长期使用Kesimpta治疗MS，患者耐受性良好, objectType=article, longId=300225, objectId=3f9e30022571, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f9e30022571, replyNumber=0, likeNumber=93, createdTime=2022-03-09, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f9e30022571, moduleTitle=长期使用Kesimpta治疗MS，患者耐受性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f9e30022571)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417745, encodeId=f66f141e745a3, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=THER ADV GASTROENTER：甲氨蝶呤单药治疗成人克罗恩病患者的短期耐受性和有效性分析, objectType=article, longId=299696, objectId=dee929969679, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dee929969679, replyNumber=0, likeNumber=102, createdTime=2022-02-28, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dee929969679, moduleTitle=THER ADV GASTROENTER：甲氨蝶呤单药治疗成人克罗恩病患者的短期耐受性和有效性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dee929969679)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417744, encodeId=0b21141e744b7, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Front Oncol：顺铂联合伊立替康一线治疗转移性或不能切除的胸腺癌疗效显著耐受性好, objectType=article, longId=294107, objectId=35b729410e5b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35b729410e5b, replyNumber=0, likeNumber=102, createdTime=2022-01-18, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35b729410e5b, moduleTitle=Front Oncol：顺铂联合伊立替康一线治疗转移性或不能切除的胸腺癌疗效显著耐受性好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35b729410e5b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417743, encodeId=8368141e743f2, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=STTT：国内多中心研究ORIENT-4证实PD-1抑制剂sintilimab（信迪利单抗）对有复发/难治性结外NK/T细胞淋巴瘤（r/r ENKTL）患者有效且耐受性良好, objectType=article, longId=293110, objectId=00a32931103c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00a32931103c, replyNumber=0, likeNumber=109, createdTime=2021-12-31, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00a32931103c, moduleTitle=STTT：国内多中心研究ORIENT-4证实PD-1抑制剂sintilimab（信迪利单抗）对有复发/难治性结外NK/T细胞淋巴瘤（r/r ENKTL）患者有效且耐受性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00a32931103c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417742, encodeId=02fb141e742fc, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Haemophilia：使用与不使用 FVIII 抑制剂的重度 A 型血友病儿童患者中 emicizumab 预防的耐受性和安全性的真实世界经验, objectType=article, longId=292247, objectId=bce929224e89, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bce929224e89, replyNumber=0, likeNumber=93, createdTime=2021-12-21, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bce929224e89, moduleTitle=Haemophilia：使用与不使用 FVIII 抑制剂的重度 A 型血友病儿童患者中 emicizumab 预防的耐受性和安全性的真实世界经验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bce929224e89)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417741, encodeId=c32c141e74177, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Pediatr Blood Cancer：放疗联合VPA和贝伐珠单抗治疗胶质瘤的耐受性良好, objectType=article, longId=292033, objectId=0686292033a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0686292033a0, replyNumber=0, likeNumber=89, createdTime=2021-12-18, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0686292033a0, moduleTitle=Pediatr Blood Cancer：放疗联合VPA和贝伐珠单抗治疗胶质瘤的耐受性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0686292033a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417740, encodeId=e35e141e74049, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Neurology：利妥昔单抗治疗乙酰胆碱受体抗体阳性重症肌无力的2期试验：安全、耐受性良好，但不可显著减少类固醇使用, objectType=article, longId=221575, objectId=e6ec2215e50a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6ec2215e50a, replyNumber=0, likeNumber=115, createdTime=2021-12-07, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6ec2215e50a, moduleTitle=Neurology：利妥昔单抗治疗乙酰胆碱受体抗体阳性重症肌无力的2期试验：安全、耐受性良好，但不可显著减少类固醇使用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6ec2215e50a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417739, encodeId=ca37141e73978, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Lancet Neurol：无功无过——间充质干细胞与安慰剂治疗多发性硬化症(MESEMS)的安全性、耐受性和活性的研究, objectType=article, longId=219450, objectId=ebb921945031, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ebb921945031, replyNumber=0, likeNumber=96, createdTime=2021-10-30, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ebb921945031, moduleTitle=Lancet Neurol：无功无过——间充质干细胞与安慰剂治疗多发性硬化症(MESEMS)的安全性、耐受性和活性的研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ebb921945031)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417737, encodeId=7483141e737a0, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Lancet Neurol：耐受性差，疗效阴性——不推荐贝沙罗汀治疗复发缓解型多发性硬化症(CCMR ONE), objectType=article, longId=219155, objectId=f5c7219155cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5c7219155cb, replyNumber=0, likeNumber=110, createdTime=2021-10-25, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5c7219155cb, moduleTitle=Lancet Neurol：耐受性差，疗效阴性——不推荐贝沙罗汀治疗复发缓解型多发性硬化症(CCMR ONE), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5c7219155cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

耐受性

2020-05-29

(审核中...)

前往app查看评论内容

#肺结节# #肺叶##耐受性#

病例分享：75岁高龄又主动脉瘤放过支架，查出肺结节并随访进展，我叫他手术，对吗？

2023-10-11发表于上海

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

JCC: 硫嘌呤治疗克罗恩病失败后硫鸟嘌呤与甲氨蝶呤可以作为二线治疗药物并有良好耐受性

2022-09-14

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Lancet：联合用药治疗糖尿病周围神经病变性疼痛的效果与单一用药相似，联合用药耐受性好

2022-08-26

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

吡非尼酮胶囊在中国肺纤维化人群中的耐受性研究

2022-07-17

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

JAMA Dermatol：Nomacopan治疗大疱性类天疱疮老年患者的耐受性良好，疗效佳

2022-07-13

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Br J Radiol：老年非黑素瘤皮肤癌患者的短疗程加速放疗耐受性良好，高剂量的效果更佳

2022-07-13

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

EBioMedicine ：CBP/β-连环蛋白抑制剂PRI-724在丙型和乙型肝炎病毒诱导的肝硬化患者中的安全性、耐受性和抗纤维化效果

2022-05-27

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

JNNP:生酮饮食治疗复发性多发性硬化症的II期研究,安全性、耐受性和潜在临床益处

2022-05-20

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

J Eur Acad Dermatol Venereol：外用非那雄胺可明显改善毛发数量，且耐受性良好

2022-05-02

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

益生元有利减肥，但随时排气很社死？加上TA，增强胃肠道耐受性！还能使益生元效果upup，改善代谢参数！

2022-04-08

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

肺动脉高压患者的运动耐受性为什么要纳入病情评估中？

2022-03-25

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

长期使用Kesimpta治疗MS，患者耐受性良好

2022-03-09

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

THER ADV GASTROENTER：甲氨蝶呤单药治疗成人克罗恩病患者的短期耐受性和有效性分析

2022-02-28

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Front Oncol：顺铂联合伊立替康一线治疗转移性或不能切除的胸腺癌疗效显著耐受性好

2022-01-18

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

STTT：国内多中心研究ORIENT-4证实PD-1抑制剂sintilimab（信迪利单抗）对有复发/难治性结外NK/T细胞淋巴瘤（r/r ENKTL）患者有效且耐受性良好

2021-12-31

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Haemophilia：使用与不使用 FVIII 抑制剂的重度 A 型血友病儿童患者中 emicizumab 预防的耐受性和安全性的真实世界经验

2021-12-21

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Pediatr Blood Cancer：放疗联合VPA和贝伐珠单抗治疗胶质瘤的耐受性良好

2021-12-18

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Neurology：利妥昔单抗治疗乙酰胆碱受体抗体阳性重症肌无力的2期试验：安全、耐受性良好，但不可显著减少类固醇使用

2021-12-07

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Lancet Neurol：无功无过——间充质干细胞与安慰剂治疗多发性硬化症(MESEMS)的安全性、耐受性和活性的研究

2021-10-30

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Lancet Neurol：耐受性差，疗效阴性——不推荐贝沙罗汀治疗复发缓解型多发性硬化症(CCMR ONE)

2021-10-25

科室
- - 订阅+
  - 更多科室
工具
服务